Indication
Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Loading your page…
Loading your page…
Melanoma
Marketing Authorisation Holder: Roche Registration GmbH
EMA Authorisation: 20/11/2015
INN: cobimetinib
AI Drug & Interaction Analysis
Free account required
Ask Osler about Cotellic: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.